TOKYO, July 17, 2025 /PRNewswire/ -- ZAMST, a global leader in premium sports bracing and support, proudly announces the renewal of its global brand ambassador partnership with NBA All-Star guard Trae Young of the Atlanta Hawks. This continued alliance marks a powerful milestone in a relationship that began in 2020, rooted in shared values of resilience, innovation, and peak performance.
"Zamst has been with me since the beginning – through every game and every step of the way. Their braces keep me protected and confident on the court, and I am honored to continue this relationship." – Trae Young
Trae Young : Setting the standard in NBA
The 2024–25 season marked another remarkable chapter for Young. Selected to his fourth NBA All-Star Game and finishing the season as top assist leader further cementing his status as one of the league's premier playmakers. Widely recognized for his deep shooting range, clutch shot-making, and elite playmaking ability, Young continues to be a driving force at the point guard position.
Off the court, he is committed to mentorship and youth development, resonating with fans around the globe.
Engineered for Greatness: Trae & ZAMST
Zamst: "Trae's exceptional performance, leadership within his team and commitment to community align perfectly with ZAMST's mission to empower athletes to perform at their highest potential. His leadership on and off the court makes him an ideal ambassador, and we are honored to support him as he continues to inspire the next generation"
Since first teaming up with ZAMST, Young has trusted flagship A2-DX ankle braces —to maintain peak condition and protect himself during games. As a global brand ambassador, Young promotes the importance of injury prevention and proper conditioning for athletes of all levels.
Explore why Trae Young trusts the A2-DX: https://www.youtube.com/watch?v=shqkbR7AHh0
ABOUT ZAMST
Zamst reinforces and protects athletes by providing premium and technical bracing products derived from innovative materials, designs and manufacturing processes. Created in 1992 by Nippon Sigmax Co., Ltd a leader in the Japanese orthopedic market, Zamst leverages its strong medical expertise to build products that maximize anatomical functionality and performance. Trusted over 30 years by elite athletes, Zamst continuously evolves to become the most authentic sports medicine and wellness brand in the industry.
The A2-DX is one of Zamst's signature ankle braces, widely trusted by professional basketball organizations and athletes across collegiate, high school and club levels. Designed for high-impact sports, it provides strong support for the ankle without limiting mobility.
Discover more on Trae Young ankle braces and other Zamst products at: http://www.zamst.us
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ZAMST renews partnership with NBA Basketball Star Trae Young as Global Brand Ambassador
ZAMST renews partnership with NBA Basketball Star Trae Young as Global Brand Ambassador
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
